Navigation Links
Novel Mechanism Insights and Additional Data on CombinatoRx Drug,Candidates to Be Presented at Upcoming EULAR Meeting

ates, the Company's ability to develop a modified release formulation of CRx-102, potential difficulty and delays in obtaining regulatory approval for the sale and marketing of its product candidates, the Company's ability to obtain additional financing or funding for its research and development and those other risks that can be found in the "Risk Factors" section of the CombinatoRx Annual Report on Form 10-K on file with the Securities and Exchange Commission and the other reports that CombinatoRx periodically files with the Securities and Exchange Commission. Actual results may differ materially from those CombinatoRx contemplated by these forward-looking statements. CombinatoRx does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.

(c) 2007 CombinatoRx, Incorporated. All rights reserved.

Contact

CombinatoRx, Incorporated
Robert Forrester, 617-301-7100
Executive Vice President, Chief Financial Officer
Fax: 617-301-7010
rforrester@combinatorx.com
or
Gina Nugent, 617-301-7099
VP, Corporate Communications and IR
Fax: 617-301-7010
gnugent@combinatorx.com


'"/>




Page: 1 2 3

Related medicine technology :

1. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
7. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
8. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
9. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
10. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
11. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
Post Your Comments:
(Date:7/24/2014)... July 24, 2014  IRIDEX Corporation (NASDAQ: ... second quarter 2014 financial results after the market closes ... with the release, the Company will host a conference ... Eastern Time on Thursday, July 31, 2014 ... other business developments. Interested parties may access ...
(Date:7/24/2014)... July 24, 2014 Omnicell, Inc. (NASDAQ: ... medication and supply management solutions and analytics software ... July 31, to discuss the Company,s Second Quarter ... Quarter 2014 earnings conference call and webcastWhen: ... Randall Lipps, chairman, president and chief executive officer ...
(Date:7/24/2014)... -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based ... results for the second quarter ended June 30, 2014. ... of $6.5 million in the second quarter of 2014, an ... , Total revenues of $13.3 million for the six months ... same period in 2013 , Total revenues generated from ...
Breaking Medicine Technology:Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... MicroCHIPS, Inc., a developer of innovative drug delivery ... Office and Trademark Office has granted U.S. Patent No. ... This patent in conjunction with U.S. Patent No. 7,070,590 ... reservoir-based medical devices used for implantable drug delivery systems. ...
... Promidian, a management consulting firm focused on ... survey findings about the increasing interest in the ... that is rapidly gaining nationwide attention for its ... care—while reducing costs. The Promidian ...
Cached Medicine Technology:MicroCHIPS Announces 35th U.S. Patent for Microreservoir-Based Drug Delivery Systems 2Promidian Survey Finds Growing Support for Patient-Centered Medical Home 2
(Date:7/27/2014)... Los Angeles, CA (PRWEB) July 27, 2014 ... of Summer Tickets at The Forum in Inglewood, California on ... new album and diehard fans can expect to hear songs from ... 5 Seconds of Summer concert in Inglewood, California at The Forum ... Find tickets starting at 10:00 a.m. today local time TicketDown.com. ...
(Date:7/27/2014)... Manchester have discovered why medication to treat asthma and pneumonia ... Medicine , show that drugs widely used to treat lung ... the UK pneumonia, which is caused by an infection, affects ... serious for babies, young children, the elderly, smokers and those ... million people in the UK are affected by asthma and ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 The North ... is estimated at $1570 million in 2014, and it ... a CAGR of 4.64%. The report incorporates the factors ... detailed expectations of growth rates and projected total expenditure. ... in the global markets. Apart from the general overview ...
(Date:7/27/2014)... 27, 2014 The European Agricultural Adjuvants ... Europe with analysis and forecast of revenue. The agricultural ... around $509.4 million in 2013 to $657.1 million by ... 2018. , Browse through the TOC of the European ... the in-depth analysis provided. It also provides a glimpse ...
(Date:7/27/2014)... July 27, 2014 Metachromatic leukodystrophy ... lysosomal storage disease which is commonly listed in ... the sphingolipidoses as it affects the metabolism of ... myelin, the fatty covering which acts as an ... peripheral nervous systems. MLD involves cerebroside sulfate accumulation. ...
Breaking Medicine News(10 mins):Health News:5 Seconds of Summer Tickets at The Forum in Inglewood (Los Angeles), CA Now Available For Sale at Ticket Down 2Health News:Drugs used to treat lung disease work with the body clock 2Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 2Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 3Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 4Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 5Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 5Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 2Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 3Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 4Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 5
... at risk for the disease, as well as ways to prevent ... osteoporosis. ,1. MYTH: Only women get osteoporosis ... this condition, theres also a very significant portion of men who ... suffer from osteoporosis, accounting for 20 percent of those diagnosed with ...
... US-based Redux Beverages said it would be marketing. Well, only it was ... drink. ,In September last year it announced the launch ... illegal drug. ,Jamey Kirby, the drink's inventor, said the name ... session at 1 o'clock in the morning. ,"It's an ...
... how nerve cells signal to one another could rewrite the ... at Weill Cornell Medical College and Yale University. ... journal Science, suggests that a key cellular enzyme called dynamin ... had previously assumed. ,Dynamin has long been a ...
... and additional risk factors for heart disease may ... two , if their current treatment combines the ... amlodipine, researchers reported at the American Heart Association's ... Outcomes Research in Cardiovascular Disease and Stroke. ...
... The Health and Family Welfare Minister, Dr. Anbumani ... Nursing Personnel today , said that under the ... requires about 200,000 nursing personnel to provide comprehensive ... achieve the requirements of NRHM, State Governments have ...
... Sensitive issues, poignant emotions and subjects that are not ... body were the mainstay of the international film festival ... on its first day Saturday. , ,Brought ... Bharati Corporation, the Mac Arthur Foundation and UNESCO, the ...
Cached Medicine News:Health News:7 Common Myths About Osteoporosis 2Health News:7 Common Myths About Osteoporosis 3Health News:'Cocaine' Turns 'Censored' and Remains 'energy Drink' 2Health News:'Cocaine' Turns 'Censored' and Remains 'energy Drink' 3Health News:Study Revises Dynamin's Role in Nerve Cell Function 2Health News:Study Revises Dynamin's Role in Nerve Cell Function 3Health News:One Pill may Be Better Than Two for Treating Patients With High Blood Pressure 2Health News:One Pill may Be Better Than Two for Treating Patients With High Blood Pressure 3Health News:Film Festival on Gender Sexuality Draws Crowds 2
... The Humphrey Field Analyzer II-i series is ... examine the patient's visual field. By using ... time is reduced by up to 70%. ... compact, ergonomic design to increase patient comfort ...
... Matrix represents the latest breakthrough in ... technology, the Humphrey Matrix will help ... evaluation and assess treatment alternatives. Enhanced ... provide complete long-term glaucoma care for ...
... Proclear Tailor Made Toric soft contact lenses let ... any other soft toric lens in a lens ... level of comfort is made possible by PC ... of phosphorylcholine (PC), a substance found naturally in ...
Preference Toric quarterly planned replacement lenses are durable, easy to handle and virtually maintenance free. Meeting the needs of those suffering from astigmatism, these soft contact lenses are ...
Medicine Products: